Michael Henderson - Jun 22, 2023 Form 3 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
Director
Signature
/s/ Jonathan Alspaugh, by power of attorney
Stock symbol
AGLE
Transactions as of
Jun 22, 2023
Transactions value $
$0
Form type
3
Date filed
6/30/2023, 05:13 PM
Next filing
Jul 17, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AGLE Stock Option (Right to Buy) Jun 22, 2023 Common Stock 1.95M $0.30 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.
F2 The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.

Remarks:

Exhibit 24 - Power of Attorney